TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

TuHURA Biosciences (NASDAQ:HURA) announced it regained compliance with Nasdaq's $1.00 minimum bid price requirement after the company's common stock closed at $1.00 or greater for 11 consecutive business days from Feb 10, 2026 through Feb 25, 2026, and Nasdaq closed the matter on Feb 26, 2026.

The company said it is progressing enrollment in its Phase 3 accelerated approval trial for IFX-2.0 in front-line Merkel Cell Carcinoma, readying TBS 2025 for a Phase 2 study in relapsed/refractory NPM1 mutated AML, and advancing preclinical proof-of-concept for immune modulating antibody drug conjugates.

Positive

• Nasdaq compliance regained: closing bid ≥ $1.00 for 11 consecutive business days (Feb 10–Feb 25, 2026)
• Phase 3 enrollment progressing for IFX-2.0 in front-line Merkel Cell Carcinoma
• Phase 2 readiness for TBS 2025 in relapsed/refractory NPM1 mutated AML

Negative

• None.

Key Figures

Nasdaq bid threshold: $1.00 per share Compliance streak: 11 consecutive business days IFX-2.0 trial phase: Phase 3 +5 more

8 metrics

Nasdaq bid threshold $1.00 per share Minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)

Compliance streak 11 consecutive business days Closing bid at or above $1.00 from Feb 10–25, 2026

IFX-2.0 trial phase Phase 3 Accelerated approval trial in front-line Merkel Cell Carcinoma

TBS 2025 trial phase Phase 2 Planned study in relapsed/refractory NPM1 mutated AML

Current share price $1.62 Price before/around compliance news publication

52-week high $4.44 Pre-news 52-week high level

52-week low $0.41 Pre-news 52-week low level

Shelf registration size $250,000,000 Mixed Form S-3 base shelf registered in Nov 2025

Market Reality Check

Price: $1.62 Vol: Volume 1,580,525 vs 20-da...

low vol

$1.62 Last Close

Volume Volume 1,580,525 vs 20-day average 3,857,571 (volume_relative 0.41) indicates lighter trading than usual ahead of this news. low

Technical Shares at $1.62 are trading below the 200-day MA of $2.12 and 63.51% under the 52-week high of $4.44, but above the 52-week low of $0.41.

Peers on Argus

HURA was down 3.57% while peers showed a mixed picture: IOBT up 5.31%, AVTX up 4...

HURA was down 3.57% while peers showed a mixed picture: IOBT up 5.31%, AVTX up 4.63%, SKYE modestly higher, ONCY down 2.73%, and PYXS flat. With no peers in the momentum scanner and mixed peer moves, trading appeared stock-specific rather than sector-driven.

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Investor conferences	Neutral	+20.0%	Announced participation in March 2026 investor conferences and webcasts.
Feb 17	IND filing	Positive	-15.0%	Filed IND for VISTA antibody TBS-2025 with planned Phase 2 AML trial.
Feb 12	Conference presentation	Neutral	+7.8%	CEO scheduled to present at Oppenheimer healthcare conference with webcast.
Feb 2	Orphan designation	Positive	-3.0%	FDA granted Orphan Drug Designation for IFx-2.0 in melanoma.
Dec 15	CVR share release	Negative	-6.0%	Triggered release of 1,539,958 shares to CVR holders after trial milestone.

Pattern Detected

Recent news, including positive regulatory and clinical milestones, has often seen price moves that diverge from the apparent positivity of the announcements, with only a dilution-linked CVR event aligning with a negative reaction.

Recent Company History

Over the last few months, TuHURA reported several catalysts: conference participation on Feb 12, 2026 and Feb 24, 2026, an IND filing for TBS-2025 on Feb 17, 2026, FDA Orphan Drug Designation for IFx-2.0 on Feb 2, 2026, and a CVR-related share release on Dec 15, 2025. Despite seemingly positive regulatory and clinical milestones, share reactions were often negative or inconsistent. Today’s Nasdaq compliance update fits into a pattern where operational progress does not always translate into supportive near-term price action.

Regulatory & Risk Context

Active S-3 Shelf · $250,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-03

$250,000,000 registered capacity

An effective mixed Form S-3 filed on Nov 3, 2025 registers up to $250,000,000 of securities, including an ATM component of up to $50,000,000, giving TuHURA flexibility to issue equity or other securities over time for working capital and corporate purposes, which can introduce dilution risk depending on usage.

Market Pulse Summary

This announcement closed out Nasdaq’s prior minimum bid price deficiency after 11 consecutive days a...

Analysis

This announcement closed out Nasdaq’s prior minimum bid price deficiency after 11 consecutive days above the $1.00 threshold, removing a listing overhang cited in the earlier Jan 30, 2026 8-K. At the same time, TuHURA continued to advance its pipeline, including a Phase 3 IFX-2.0 trial and a planned Phase 2 study for TBS 2025. Investors may monitor future use of the $250,000,000 shelf, upcoming trial milestones, and any further Nasdaq communications as key data points.

Key Terms

minimum bid price requirement, phase 3, accelerated approval, merkel cell carcinoma, +3 more

7 terms

minimum bid price requirement regulatory

"regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

phase 3 medical

"a Phase 3 immuno-oncology company developing novel therapeutics"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

accelerated approval regulatory

"Phase 3 accelerated approval trial for IFX-2.0 in front-line Merkel Cell Carcinoma"

Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.

merkel cell carcinoma medical

"Phase 3 accelerated approval trial for IFX-2.0 in front-line Merkel Cell Carcinoma"

Merkel cell carcinoma is a rare, fast-growing form of skin cancer that starts in cells near the base of the skin and often spreads quickly to nearby tissues and organs. For investors, it matters because treatments for this aggressive disease can create high-value opportunities or risks: successful drugs or tests can unlock significant revenue and partnerships, while failed trials or regulatory setbacks can sharply affect a biotech company’s prospects — like a single critical test determining whether a new product succeeds or stalls.

vista inhibiting antibody medical

"TBS 2025, our VISTA inhibiting antibody, for the initiation of our Phase 2 study"

A VISTA-inhibiting antibody is a lab-made protein that binds to and blocks VISTA, a molecule that acts like a brake on certain immune cells. By releasing that brake, these antibodies aim to boost the body’s immune attack on tumors or other targets, similar to taking your foot off a car’s brake to let it move forward. Investors watch them because successful candidates can become valuable new immunotherapy drugs, but they carry typical clinical and regulatory risks tied to trial results and safety.

antibody drug conjugates medical

"advance toward preclinical proof-of-concept in our first-in-class immune modulating antibody drug conjugates"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

immuno-oncology medical

"a Phase 3 immuno-oncology company developing novel therapeutics"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

AI-generated analysis. Not financial advice.

TAMPA, Fla., Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26, 2026, it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the "Listing Rule"). Nasdaq confirmed that for the last 11 consecutive business days, from February 10, 2026, through February 25, 2026, the closing bid price of the Company's common stock has been at $1.00 per share or greater, and as a result, the matter is now closed.

"We are pleased to have regained full compliance with Nasdaq's listing standards and continue to remain fully focused on advancing our pipeline of assets," said Dr. James Bianco, President and CEO of TuHURA Biosciences. "We continue to progress enrollment in our Phase 3 accelerated approval trial for IFX-2.0 in front-line Merkel Cell Carcinoma; are readying TBS 2025, our VISTA inhibiting antibody, for the initiation of our Phase 2 study in relapsed/refractory NPM1 mutated AML; and are continuing to advance toward preclinical proof-of-concept in our first-in-class immune modulating antibody drug conjugates."

About TuHURA Biosciences, Inc. 
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.

TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

In addition to its innate immune agonist product candidates, TuHURA acquired TBS-2025 in its merger with Kineta Inc. on June 30, 2025. TBS-2025 is a VISTA inhibiting mAb moving into Phase 2 development in mutNPM1 r/r AML. In addition, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-Looking Statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases, you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely," or the negative or plural of these words or similar expressions. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the SEC, which are available on TuHURA's website and at www.sec.gov.

The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Investor Contact: 
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302699243.html

SOURCE TuHURA Biosciences, Inc.

FAQ

How did TuHURA (HURA) regain Nasdaq compliance on Feb 26, 2026?

TuHURA regained compliance after its common stock closed at $1.00 or greater for 11 consecutive business days. According to the company, the relevant period was Feb 10, 2026 through Feb 25, 2026 and Nasdaq closed the matter on Feb 26, 2026.

What does Nasdaq compliance mean for TuHURA (HURA) shareholders?

Nasdaq compliance means the company remains listed and avoids delisting procedures, maintaining liquidity and market access. According to the company, Nasdaq confirmed the $1.00 minimum bid-price requirement was met for the required 11 consecutive business days.

What clinical programs did TuHURA (HURA) highlight alongside the Nasdaq update?

TuHURA noted progress in three programs: Phase 3 enrollment for IFX-2.0, Phase 2 readiness for TBS 2025, and preclinical work on antibody drug conjugates. According to the company, these efforts remain priorities following compliance confirmation.

When did TuHURA report the Nasdaq compliance confirmation for HURA stock?

The company reported receiving Nasdaq's written confirmation on Feb 26, 2026 that the compliance matter is closed. According to the company, the 11-day compliance window ran from Feb 10 through Feb 25, 2026.

Will the Nasdaq compliance affect TuHURA (HURA) clinical trial timelines?

The announcement does not state any timeline changes for trials; it affirms continued focus on development programs. According to the company, enrollment and study preparations for IFX-2.0 and TBS 2025 are ongoing as previously described.